Ocular Therapeutix (OCUL)

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Company profile

Ticker

OCUL

Exchange

NASDAQ

Website

www.ocutx.com

CEO

Antony Mattessich

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

Former names

I-THERAPEUTIX INC

SEC CIK

0001393434

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Ocular Therapeutix Europe B.V. • Ocular Therapeutix Securities Corp. ...

OCUL stock data

1M 1Y 5Y

News

From Benzinga Pro

Ocular Therapeutix's Return On Capital Employed Overview

6 Jun 22

Ocular Therapeutix (NASDAQ:OCUL) brought in sales totaling $13.19 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 225.77%, resulting in a loss of $12.54 million.

Stocks That Hit 52-Week Lows On Friday

27 May 22

During Friday's session, 59 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

26 May 22

On Thursday, 94 companies set new 52-week lows.

Expert Ratings for Ocular Therapeutix

10 May 22

JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $20

10 May 22

Press releases

From Benzinga Pro

Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

9 Jun 22

Leading Ophthalmologist and Experienced Industry Executive to Advance Development of Innovative Corneal Endothelial Cell Therapy Aurion Biotech, whose mission is to restore vision to millions of patients with its

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

8 Jun 22

Peter K. Kaiser, M.D., a world-renowned ophthalmologist and retinal disease expert, to serve as Chief Medical Advisor – Retina Rabia Gurses Ozden, M.D. promoted to Chief Medical Officer Michael Goldstein, M.D. to

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference

1 Jun 22

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau

9 May 22

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

9 May 22

Analyst ratings and price targets

Last 3 months

Average target

$15.33

Low target

$10.00

High target

$20.00

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

9 May 22

26 Jun 22

31 Dec 22

Financial summary

Financial statements Chart OCUL financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	147.18M	147.18M	147.18M	147.18M	147.18M	147.18M
Cash burn (monthly)	6.25M	5.33M	5.94M	6.3M	6.2M	5.57M
Cash used (since last report)	17.93M	15.29M	17.06M	18.09M	17.79M	15.97M
Cash remaining	129.25M	131.89M	130.12M	129.09M	129.39M	131.21M
Runway (months of cash)	20.7	24.7	21.9	20.5	20.9	23.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

OCUL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Jun 22	Hong Seung Suh	Common Stock	Grant	Acquire A	No	No	0	8,933	0	8,933
16 Jun 22	Hong Seung Suh	Stock Option Common Stock	Grant	Acquire A	No	No	3.43	26,800	91.92K	26,800
16 Jun 22	Heier Jeffrey S.	Common Stock	Grant	Acquire A	No	No	0	8,933	0	47,933
16 Jun 22	Heier Jeffrey S.	Stock Option Common Stock	Grant	Acquire A	No	No	3.43	26,800	91.92K	26,800
16 Jun 22	Lindstrom Richard L MD	Common Stock	Grant	Acquire A	No	No	0	8,933	0	108,402
16 Jun 22	Lindstrom Richard L MD	Stock Option Common Stock	Grant	Acquire A	No	No	3.43	26,800	91.92K	26,800
16 Jun 22	Warden Charles M	Common Stock	Grant	Acquire A	No	No	0	8,933	0	48,464
16 Jun 22	Warden Charles M	Stock Option Common Stock	Grant	Acquire A	No	No	3.43	26,800	91.92K	26,800
16 Jun 22	Williams Leslie J.	Common Stock	Grant	Acquire A	No	No	0	8,933	0	13,433
16 Jun 22	Williams Leslie J.	Stock Option Common Stock	Grant	Acquire A	No	No	3.43	26,800	91.92K	26,800

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

OCUL institutional ownership history Ownership history

56.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	128	139	-7.9%
Opened positions	14	27	-48.1%
Closed positions	25	28	-10.7%
Increased positions	44	51	-13.7%
Reduced positions	42	42	–

13F shares	Current	Prev Q	Change
Total value	240.84M	1.57B	-84.7%
Total shares	43.64M	41.43M	+5.3%
Total puts	167.4K	279.4K	-40.1%
Total calls	153.4K	306.7K	-50.0%
Total put/call ratio	1.1	0.9	+19.8%

Largest owners	Shares	Value	Change
Opaleye Management	5.97M	$29.58M	0.0%
Summer Road	5.94M	$29.43M	+3.1%
BLK Blackrock	5.07M	$25.09M	-1.0%
Vanguard	4.2M	$20.77M	+2.9%
Deltec Asset Management	2.08M	$10.28M	-0.9%
STT State Street	1.7M	$8.44M	-1.5%
Citadel Advisors	1.69M	$8.38M	+10.5%
Geode Capital Management	1.36M	$6.75M	+3.5%
Emerald Advisers	1.29M	$6.4M	+22.1%
Emerald Mutual Fund Advisers Trust	1.09M	$5.41M	+9.6%

Largest transactions	Shares	Bought/sold	Change
FHI Federated Hermes	622.28K	+622.28K	NEW
Millennium Management	735.73K	+443.54K	+151.8%
Renaissance Technologies	510.81K	+430.71K	+537.7%
Los Angeles Capital Management & Equity Research	350.29K	+350.29K	NEW
Ubs Oconnor	300K	+300K	NEW
Emerald Advisers	1.29M	+234.18K	+22.1%
BMO Bank of Montreal	210.94K	+210.94K	NEW
Endurant Capital Management	923.96K	+206.82K	+28.8%
MS Morgan Stanley	221.66K	-200.71K	-47.5%
Summer Road	5.94M	+180K	+3.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

EyePoint Pharmaceuticals • Aerie Pharmaceuticals • Aldeyra Therapeutics • Ocugen • Kodiak Sciences • Kala Pharmaceuticals • Apellis Pharmaceuticals • Adverum Biotechnologies • Sight Sciences • Graybug Vision

Management Discussion

We are a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary bioresorbable hydrogel-based formulation technology. Core to our strategy is (i) to continue to build upon our experience commercializing ophthalmology products that can be administered primarily in the surgical and/or office settings and (ii) to continue to develop a clinical pipeline of innovative ophthalmology products that address large areas of unmet need.
We currently have two FDA-approved products in commercialization in the United States: DEXTENZA, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain and ocular itching associated with allergic conjunctivitis, and ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. We also have product candidates in preclinical and clinical development designed to utilize our proprietary, bioresorbable hydrogel technology to treat retinal diseases including wet age-related macular degeneration, or wet AMD; glaucoma and ocular hypertension; and ocular surface diseases and conditions including dry eye disease.
We incorporate therapeutic agents that have previously received regulatory approval from the U.S. Food and Drug Administration, or FDA, including small molecules and proteins, into our proprietary bioresorbable hydrogel-based formulation technology in our internal drug development activities, with the goal of providing local programmed release to tailor the duration and amount of drug to be delivered to the eye. We believe that our local programmed-release drug delivery technology has the potential to treat conditions and diseases of both the front and the back of the eye and can be administered through a range of different modalities including intravitreal implants, suprachoroidal implants, intracameral implants and intracanalicular inserts.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: belonging, bulbar, bundled, cautioned, compelling, comprised, Cutler, Dorr, Exudation, Hale, highlighted, hyperemia, inflation, invoiced, ITT, optometric, photographic, Pickering, preserving, ratio, rolled, RSU, signal, sister, sponsorship, subcontractor, Super, titled, unmet, unsatisfied, Wilmer, WilmerHale

Removed: abandon, abroad, abuse, abusive, ACA, academic, accelerated, accept, accident, Accountability, accruing, accuracy, accurate, achievement, acquired, acquirer, acquisition, acted, acuity, add, added, adding, Additionally, addressed, adequacy, adequately, adhere, adjusted, administrator, adult, advancement, advantage, adversarial, advisory, advocating, affirmative, affirmatively, affirmed, affordability, Affordable, afforded, aflibercept, Agency, aggressive, agree, agreeing, ahead, Aid, aim, alleging, alter, altogether, amend, amending, American, analytical, announcement, annually, Antony, appeal, appealed, applied, apply, applying, appointing, approach, approve, arbitration, Area, argument, arising, arm, arrange, arranging, art, ARVO, ASC, ascertain, Asia, asserted, asserting, assertion, assessing, assign, assigned, assigning, assignment, assistance, assuming, assure, attain, attempted, attending, attention, attestation, attract, attrition, augment, authorization, authorize, authorizing, automatic, avoiding, aware, bandage, bar, Bedford, begin, begun, Benchmark, beneficial, bidding, Biden, biodegradable, biologic, biometric, blurred, board, body, border, branded, breached, breadth, Brexit, bribery, bring, broad, broadly, brought, Budget, built, bulk, California, called, Canada, capable, capitalize, carefully, carried, carry, cast, catastrophic, categorized, CCPA, CE, cease, ceased, ceasing, certainty, certificate, cGMP, chain, challenge, challenged, challenging, charged, charter, chemical, children, Circuit, civil, claim, claimed, claiming, clear, clearance, cleared, closed, CMS, code, coded, coherence, collaborate, collaborative, collaborator, collateralized, collect, collected, collection, combining, commence, commenced, comment, commerce, commercialized, commissioned, commit, Committee, commonly, communicate, community, comparative, compare, comparing, comparison, compete, competent, competing, competitor, complementary, complex, compliant, complicating, complied, comply, complying, composition, compromise, compromised, computer, concealing, concentrated, concession, conclude, conclusive, Conference, confidence, confidential, confidentiality, confirm, confirmation, confirmed, conflict, conform, congressional, consent, considerable, consistently, constrain, construe, consult, consumer, contamination, contemplate, contested, continuation, continuously, contracting, contradictory, controlled, controlling, convenient, Cooperation, correct, corrective, correspondingly, Corrupt, corruption, Cosmetic, costly, counsel, counter, country, court, covenant, coverage, covered, covering, CPT, create, created, credible, criminal, CRL, Crosby, cultural, cumulative, curtail, curtailment, damage, damaged, dated, debarment, decide, decided, decision, declared, decline, declined, declining, decreased, decreasing, decree, dedicate, deductibility, deduction, deem, deemed, deemphasize, defect, defend, defendant, defended, defense, defer, deferral, defraud, delayed, demand, demonstrate, denied, Department, departure, depressing, depth, DER, derivation, design, designing, desirable, desire, destroyed, destruction, detailed, detect, detention, deter, determination, deterrent, deviation, devise, devote, devoted, DEXYCU, diabetic, diagnosed, diagnostic, difficulty, digit, diligence, dilute, dilution, dilutive, diminish, diminished, directing, disadvantage, disclose, discounting, discourage, discovered, discovering, discovery, discrete, discretion, disgorgement, dismissed, disposal, dispose, disproportionate, disrupt, disrupted, dissemination, dissuade, distract, distracting, distraction, distribute, distributed, distributing, district, diversify, diversion, divert, DME, documentation, documented, documenting, DOJ, domain, Dr, draft, drop, duct, durability, ease, economically, edema, EEA, effected, effectively, efficient, eIND, electrical, eligibility, eliminated, elimination, eluting, emerging, employed, employer, employment, enact, enacted, enactment, encounter, encourage, encumbering, enforce, enforceability, enforced, enforcement, English, enhance, enhanced, enlarge, enrolling, ensuring, environmental, error, escalating, ESPP, essential, essentially, establishment, ethical, EU, Europe, European, eventual, evolve, evolving, examination, exceed, exclude, exclusion, exclusively, exclusivity, execute, executing, execution, exempt, exemption, exercised, exhibited, exist, existence, exit, expensive, expertise, expired, exploratory, explore, exploring, export, expose, expressed, extending, extreme, extremely, eylea, face, facilitate, fact, factor, factual, fail, failed, failing, failure, fairly, fall, fallen, false, FASB, fashion, faster, favor, favored, FCA, FCPA, FDCA, fearful, feasibility, feature, federal, fee, fewer, FFCR, filer, finalized, Finally, firm, flare, flat, flexibility, float, floor, flow, fluctuate, forego, foreign, formal, formula, formulating, forthcoming, forward, found, framework, fraud, fraudulent, freely, frequency, frustrate, fulfilled, functioning, funded, furlough, furnish, gaining, gap, gathered, GDPR, generic, genetic, globally, glycol, govern, governance, governed, governing, governmental, graph, greater, group, guarantee, half, halt, hand, handling, harmed, harmful, head, headcount, healthcare, hear, hedging, heightened, higher, hinder, HIPAA, hire, hiring, historically, hold, holding, hostile, hypopyon, Icon, IDE, identical, identifiable, Identity, illegally, impair, impaired, impede, implement, implemented, implementing, import, importance, importation, impose, imposed, imposition, imprisonment, improper, improperly, inability, inadequate, inappropriate, Incept, incidence, incident, inconclusive, inconvenient, incorporation, incorrectly, increasing, increasingly, incremental, indefinitely, indemnify, independent, independently, individually, induce, inducement, inexpensively, inflammatory, influenced, influencing, informational, informed, infringe, infringed, infringement, infringing, inherently, inhibit, initiating, initiative, injunction, injury, inserting, inseverable, inside, inspected, inspection, inspectional, institute, instituted, institutional, insufficient, Integra, integrity, intense, intensity, intensive, intentional, inter, interference, interpretation, interpreted, interrupt, interrupted, introduction, invalid, invalidate, invalidated, invalidation, invalidity, invent, invention, inventor, inventorship, invested, investigating, investigation, investigational, investigator, invite, involving, irritation, issuable, issue, jeopardize, Jonathan, judge, judicial, jurisdiction, Justice, justify, kind, Kingdom, knowingly, labeled, labeling, laboratory, lack, lag, largely, larger, largest, launching, lawfully, led, legislation, legislative, lengthy, lessen, letter, liable, LIBOR, licensee, lieu, likelihood, likewise, link, liquefied, list, listing, literature, locate, located, location, lodge, long, lose, lost, lt, maintained, managed, managerial, mandate, mandatory, manner, manufacturer, marginal, marketable, marketed, marketer, marketplace, Mattessich, mature, McCarter, measuring, mechanism, media, Medicaid, medical, medically, Medicare, medication, medicinal, meet, member, merging, merit, mg, MidCap, minimal, minimum, misappropriated, misappropriation, misconduct, mitigation, moderately, modest, modestly, modification, modify, modulate, monetary, monitoring, morale, motivate, movement, narrow, narrowed, narrowly, nasolacrimal, nation, nationwide, natural, negatively, negotiate, negotiated, newly, NOL, nominal, noncompliance, nonrenewal, Northern, noteworthy, notification, notified, NSR, numerically, obligating, occlusion, occur, OCT, offered, official, offshore, onsite, operation, opposition, optical, Oral, Orange, originally, outline, outpatient, output, oversee, oversight, PA, packaging, paragraph, parallel, partial, partnering, PAS, passing, patentability, patentable, patenting, paying, PEG, pending, people, percentage, perception, permanent, permanently, permit, permitting, person, personal, perspective, pertaining, pertinent, pharmacoeconomic, pharmacovigilance, physical, pill, placebo, play, pocket, poison, policy, political, polyethylene, pool, Portability, portion, pose, post, postpone, potent, practical, practice, pre, preclude, predetermined, predictive, preempted, preissuance, prejudice, premarket, prematurely, premium, prepaid, preponderance, prescribe, prescribed, prescribing, prescription, presence, presenting, President, presidential, prevail, prevalence, prevalent, prevented, preventing, pricing, prioritization, prioritize, prioritizing, priority, privacy, problem, proceed, proceeding, processing, produce, produced, profit, profitable, profitably, progression, prohibit, prohibited, prolong, prolonged, promise, Promotional, promptly, promulgated, pronounced, properly, prophylactic, propose, proposed, prosecute, prosecuted, prosecution, prostaglandin, protected, protecting, protocol, protracted, proven, provision, provoke, proximal, proximity, PTAB, publication, publicity, publicly, published, purity, pursuit, put, qualified, qualifying, question, qui, quickly, radioactive, raw, reach, reaching, reaction, recall, recognizing, recommendation, recommending, reconsider, reconsideration, recording, recordkeeping, recoup, recover, recovery, recruit, recruiting, recurrence, redesign, reexamination, referral, reform, refrigerated, refusal, refuse, Regeneron, regime, register, registered, registration, registry, regulate, reimburse, reinstated, rejected, rejection, relate, relaxation, relaxing, relevant, reliability, reliably, relied, relief, relieve, relieved, relocate, relocated, relocation, reluctance, rely, remain, remanded, remediate, remove, removed, remuneration, render, renew, repatriated, repay, repeal, repealed, repeat, repeated, replace, replacing, replicated, reposition, representing, reprioritize, reproduce, reputation, reputational, request, requested, researching, Reserve, reserved, resolution, resolved, resource, respond, responded, responsibility, responsible, restitution, restoration, restrict, restructured, restructuring, retained, retaining, retroactively, retrospective, reviewing, revised, revocation, reward, robust, role, ruled, rulemaking, ruling, RVO, safe, safeguarding, safely, safer, satisfaction, satisfactorily, schedule, scheduled, scheme, Schirmer, scientific, scrutiny, secret, secured, securing, seeking, seizure, Senate, sensitive, sequester, served, servicing, serving, shareholder, sharing, shift, shipping, shorten, shortened, shortly, showing, shut, shutdown, side, Similarly, SISPQ, site, size, slight, slowdown, slower, softened, soliciting, sought, specifically, spectral, spend, spending, spiked, spread, ST, stability, stated, statute, statutory, stemming, step, sterilization, steroid, stinging, stop, storage, stored, Street, strength, strict, strong, stronger, structural, structure, submission, submitted, subsequent, substance, substantive, succeed, suffer, sufficiently, suggest, suit, suitable, Sunshine, supervisory, supplement, supplier, Supreme, surveillance, susceptible, suspend, suspension, sustain, sustained, system, tam, tasked, taxable, taxation, Taxpayer, teaching, tear, tearing, technical, teen, telecommunication, teleconference, temperature, temporarily, tentative, terrorism, test, therapy, threat, threshold, timeframe, tip, tolerability, tomography, top, tort, toxic, toxicity, tracking, Trademark, tradename, traditional, train, training, transition, transitional, transitioning, transmission, transparency, transport, traveling, treating, treble, trend, tribunal, trillion, Trump, twelve, type, ultimate, ultimately, unacceptable, unanticipated, unauthorized, unavailable, unclear, unconstitutional, undergoing, undermine, undesirable, unenforceable, unexpected, unfavorable, unforeseen, unintended, Union, unknown, unlocked, unmanaged, unnecessarily, unpatentability, unpatented, unpredictable, unrelated, unsatisfactory, unsuccessful, untitled, unused, unwilling, upgrade, USPTO, vaccination, validate, validated, validating, validity, vary, varying, vascular, VEGF, vein, venue, verified, version, viewed, violate, violated, violation, Virtual, virtually, visibility, vision, visit, visualize, visualized, volatile, volatility, voluntary, vulnerable, waiting, waive, Wall, war, warning, waste, whichever, whistleblower, wide, widely, widespread, willfully, withdrawal, withdrawn, withdrew, Wong, worker, working, worldwide, written

From filing 10-Q 2022 Q1

Financial reports

View all